Bayer and Teva have lost their challenge to Indian drug maker Cipla’s extension of its patent for an allergy medication, with IP Australia finding a failure to pay renewal fees on time was due to a genuine error.
For information on rights and reprints, contact subscriptions@lawyerly.com.au